For example, the GPER antagonist, G36, delays the estrogen-dependent outgrowth of transplanted ER−/GPER+ endometrial carcinoma in mice [65], while the GPER agonist, G1, has been shown to attenuate the growth of patient-derived xenografts of pancreatic ductal adenocarcinoma [77]. Here, GPER1 is linked to endometrial carcinoma.